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The design, synthesis and evaluation of 24 isoindolinones as potential inhibitors 
of the MDM2-p53 interaction is described.  
The most potent inhibitor NU8231 (ELISA: IC50 = 5.3 ± 0.9 µM) displays 
cellular activity in human SJSA cells. 
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Abstract – A series of 2-N-alkyl-3-aryl-3-alkoxyisoindolinones has been synthesised and evaluated as 
inhibitors of the MDM2-p53 interaction. The most potent compound, 3-(4-chlorophenyl)-3-(4-hydroxy-
3,5-dimethoxybenzyloxy)-2-propyl-2,3-dihydroisoindol-1-one (NU8231), exhibited an IC50 of 5.3 ± 0.9 
µM in an ELISA assay, and induced p53-dependent gene transcription, in a dose dependent manner, in 
the SJSA human sarcoma cell line.    
 
The p53 tumour suppressor acts as a ‘guardian of the genome’ by reacting to cellular stress, such as 
hypoxia and DNA damage. Such stresses increase cellular levels of p53 and activate its transcriptional 
function to drive the expression of a number of genes that govern progression through the cell cycle, the 
initiation of DNA repair, and programmed cell death.1,2 The activity of p53 is tightly regulated by the 
MDM2 protein, the gene for which is itself regulated by p53. MDM2 binds to the p53 transactivation 
domain, blocking the transcriptional activity of p53 and ubiquitylating the MDM2-p53 complex to target 
it for proteosomal destruction. In normal cells the balance between active p53 and inactive MDM2-bound 
p53 is maintained by this negative feedback loop.3,4 The X-ray crystal structure of MDM2 bound to a p53 
peptide corresponding to the transactivation loop, reveals a hydrophobic pocket on the surface of MDM2, 
into which the Phe19, Trp23, and Leu26 residues of p53 bind.5 Inactivation of p53 through mutation is 
frequently found in a wide range of common sporadic cancers. However, around 7% of human tumours 
show evidence of amplification and overexpression of the MDM2 gene resulting in suppression of 
functional p53, promoting transformation and uncontrolled tumour growth.6 Inhibitors of the MDM2-p53 
binding interaction would be expected to restore normal p53 activity in MDM2 overexpressing cells and 
thus exert an anti-tumour effect.7 A number of inhibitors of the MDM2-p53 interaction have been 
reported including potent peptide inhibitors,8 the natural product chlorofusin,9 and small molecules 
including the recently described ‘nutlins’.10,11  
Here we describe inhibitors of the MDM2-p53 interaction, based on an isoindolinone scaffold. 
Preliminary screening studies, using an in vitro p53-MDM2 binding assay, identified compounds 1a and 
2a,b as modest inhibitors of the p53-MDM2 interaction (IC50 ~ 200 µM). These compounds also 
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displayed growth inhibitory activity in the NCI 60 cell-line screen and, importantly, were COMPARE 
negative with respect to any known class of antitumour agents.12 In this paper, we report a programme of 
focussed library synthesis, incorporating in silico ligand design, resulting in the discovery of novel 
inhibitors of the MDM2-p53 interaction. 
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Using the published structure of the MDM2-p53 binding site,5 we have employed computational 
methods, and focussed library synthesis based on the isoindolinone template, to develop compounds with 
improved inhibitory activity. These studies have resulted in the identification of a number of inhibitors 
(Table 1) with increased potency over the preliminary compounds (1a and 2a,b).  
Briefly, the determination of single, low-energy binding modes for 1a and 2b was attempted by 
docking the compounds into the published crystal structure of MDM2 (1YCR)5 using easyDock.13 A 
single plausible binding mode was chosen for each compound, and the position of the isoindolinone 
scaffold was preserved during the following virtual screen of new substituents. The binding interaction 
between ligand and receptor was explored using a simulated annealing optimisation of an empirical free-
energy function using the program Skelgen.14 Reagents able to form at least one additional H-bond with 
target residues of MDM2 were selected as ‘virtual hits’ and suggested for synthesis, a selection of which 
were synthesised. Comparison of the inhibitory activity of these synthesised ‘virtual hits’ with a set of  
isoindolinones bearing randomly selected substituents revealed no significant difference in activity 
between the two sets (data not shown). 
At this point, the binding mode determination was revisited with the six most active compounds 
synthesised (Table 1). The six lead compounds were docked into the MDM2 crystal structure 1YCR, 
using the programs easyDock13 and GOLD.15 It was impossible to distinguish a single preferred binding 
mode from the large pool of docking solutions. Previously, it has been shown that the probability of 
predicting the experimental binding mode correctly increases significantly when multiple binding modes 
are considered.16 Therefore, a total of 24 (6 per compound x 2 per stereoisomer x 2 per docking program) 
high scoring, unique binding modes were selected as starting points for a second round of virtual 
screening. Again, reagents able to form additional hydrogen bonds with the protein were suggested for 
synthesis. 
Table 1: Seed compounds used in the second round of binding mode determinations. 
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In order to validate this approach 57 hit compounds were selected, including substituents unique to 
each binding mode. The majority of these compounds were synthesised and assayed for inhibition of  
MDM2-p53 binding using the ELISA format assay. A number of compounds that displayed improved 
activity were identified including 2e, 2f and 2g (Table 2). 
Consideration of these results and others from additional isoindolinones synthesised as part of random 
libraries, enabled the design of a combinatorial array of compounds bearing the N-2 and C-3 substitutents 
that appeared to confer improved activity. The substituents chosen were: Ar = phenyl,  
4-(2-trimethylsilylethoxy)methoxyphenyl, and 4-chlorophenyl; R1 = n-propyl, benzyl, and 2-
acetamidoethyl; R2 = 4-t-butylbenzyloxy, 3,5-dimethoxy-4-hydroxybenzyloxy, 2-(2-pyridyl)ethoxy, and 
3-hydroxypropoxy. 
Compounds 2a-z were prepared according to Methods A, B and C (Scheme 1). The appropriate 
benzoylbenzoic acids (3) were converted into the the ψ-acid chlorides (4), under Vilsmeier conditions, 
and then condensed with the R1-primary amine to give the 4-hydroxyisoindolinone (5). Compound 5 was 
converted into the chloride and subsequently reacted with R2-alcohol in the presence of base (Et3N or 
K2CO3) to give 2d,e,g-m,o-r, and 2u,v (Method A).17 Alternatively, compound 5 was converted into the 
unstable chloride and trapped with benzylmercaptan to give the stable thioether (6). This was activated to 
nucleophilic displacement on treatment with N-iodosuccinimide (NIS) in the presence of catalytic 
camphorsulfonic acid (CSA), and reacted in situ with the appropriate R2-alcohol to give 2a,f,n,s,t. 
Compounds 2w-z were prepared according to Method C (Scheme 1). Directed-ortho-metallation of n-
propylbenzamide (7) and reaction with the appropriate benzoate ester afforded the hydroxyisoindolinone 
5, which was converted into the target isoindolinone as for Method A. The final compounds 2h-z were 
isolated and tested as racemic mixtures.18 
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Scheme 1: Reagents - Method A: a) SOCl2, cat. DMF, THF; b) R1NH2, THF; c) i) SOCl2, cat. DMF, 
THF; ii) R2OH, THF, Et3N or K2CO3. Method B: d) i) SOCl2, cat. DMF, THF; ii) PhCH2SH, THF; e) 
NIS, cat. CSA, THF, R2OH. Method C: f) R1-NH2, g) s-BuLi, ArCOOEt, THF. 
 
Compounds were assayed for inhibition of the MDM2-p53 interaction using a 96-well plate binding 
assay (ELISA) with a luminometric detection end-point. Briefly, 96-well plates were coated with 
streptavidin followed by biotinylated IP3 peptide (b-IP3: Biotin-Met-Pro-Arg-Phe19-Met-Asp-Tyr-Trp-
Glu-Gly-Leu26-Asn-NH2).19 Control experiments consisted of both 5% DMSO carrier alone as a negative 
control and 100nM active peptide (AP-B: Ac-Phe19-Met-Aib-Pmp-6-Cl-Trp-Glu-Ac3-Leu26-NH2) as a 
positive control peptide antagonist of the MDM2-p53 interaction (IC50 = 5 nM).8 Compounds and 
controls were pre-incubated at 20 oC for 20 min with MDM2, before transfer of the MDM2-compound 
mixture to the b-IP3 streptavidin plates, and incubation at 4 oC for 90 min. After washing to remove 
unbound MDM2, each well was incubated at 20 oC with a buffered solution of primary anti-MDM2 
antibody (Ab-5, Calbiochem), then washed, and incubated at 20 oC with a solution of secondary 
horseradish peroxidase (HRP) conjugated antibody (Dako), and washed again. The HRP activity was 
measured by enhanced chemiluminesence (ECLTM, Amersham Biosciences) using the oxidation of the 
diacylhydrazide substrate, luminol, to generate a quantifiable light signal. The luminol substrate together 
with enhancer was automatically injected into each well and the relative luminescence units (RLU) 
measured over a 30 second interval using a Berthold MicroLumat-Plus LB 96V microplate luminometer. 
The percentage MDM2 inhibition at a given concentration is calculated as the (RLU detected in the 
compound treated sample ÷ RLU of DMSO controls) x 100. The IC50 was calculated using a plot of % 
MDM2 inhibition vs concentration and is the average of three independent experiments. The results are 
presented in Table 2. 
 In comparison with the lead compounds bearing an unsubstituted phenyl group at the C3 position 
(2d,e and g), none of the newly synthesised compounds displayed improved potency, with only the 
syringic alcohol derivative 2k and the 2-(2-pyridyl)ethoxy derivative 2m showing inhibition comparable 
with the 4-t-butylbenzyloxy derivative 2d. In the 3-(4-chlorophenyl) series, the N-propyl substituted 3-
hydroxypropoxy derivative 2r was equipotent with the lead N-benzyl compound 2c. In contrast, the N-
propyl substituted 2-(2-pyridyl)ethoxy derivative 2s was significantly less potent than the lead N-benzyl 
compound 2f. The reverse trend was observed for the N-propyl syringic alcohol derivative 2q, which was 
significantly more potent than the N-propyl derivative 2o. Interestingly, for the syringic alcohol 
derivatives, the 4-chloro substituent was favourable in the N-propyl series (2k and q) but resulted in a loss 
of potency in the N-benzyl series (2i and q). In the N-ethylacetamido series, the 3-(4-chlorophenyl) 
derivatives (2v and w) were significantly less potent than the lead 2g. In the light of these disappointing 
results, and the difficulties encounted with the synthesis of these derivatives, this series was abandoned. 
Similarly, in the 4-(2-trimethylsilylethoxy)methoxyphenyl series, none of the compounds synthesised 
(2v-z) displayed improved potency compared with the lead 1b and the series was not completed. 
The increased potency observed for the 4-chlorophenyl compound 2q, is consistent with the predicted 
binding mode for the parent 2g, which is seen bound to MDM2 with the phenyl ring occupying the 
tryptophan binding pocket, the N-propylisoindolinone in contact with a broad, shallow, hydrophobic cleft, 
and the phenolic OH of the syringic alcohol making an H-bond to the backbone of Tyr100 on MDM2 
(Figure 1). The importance of the tryptophan binding pocket for affinity has been demonstrated 
previously by the potent activity of the AP peptide,8 and the Nutlin series.10,20 Experiments to confirm the 
binding mode of 2q are ongoing.  
The most potent compound identified, 2q (NU8231; IC50 = 5.3 ± 0.9 µM), was selected for further 
evaluation. SJSA cells, in which the MDM2 gene is amplified, were treated with increasing 
concentrations (5, 10 and 20 µM) of 2q. Cells were lysed at 6 hours and protein extracts analysed by 
Western immunoblotting for p53, p21WAF1, and actin (Figure 2). There was a dose dependent increase in 
MDM2 and p21, consistent with p53 activation. No change was observed for p53 levels or the actin 
controls. 
In summary, we have discovered interesting structurally-novel isoindolinone antagonists of the 
MDM2-p53 protein-protein binding interaction. The most potent compound 2q has an IC50 of 5.3 ± 0.9 
µM in a cell-free binding assay (ELISA) and shows dose-dependent induction of MDM2 and p21 when 
used to treat an intact MDM2 amplified human sarcoma cell line. Further development of these 
compounds is in progress. 
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Figure 1: A – Model of the low energy binding mode of 2g bound to MDM2; B – Pharmacophore 
model of 2q bound to MDM2. 
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Figure 2: Western blot from SJSA cells treated with 2q (U: untreated; D: DMSO control; 5, 10, 20 µM 
compound 2q) 
 
Table 2: Inhibition of the MDM2-p53 binding interaction by isoindolinones.  
Compound Method Ar R1 R2 IC50 (µM) 
2c B Cl  OH 15.9 ± 0.8 
2d A Ph   92 ± 11 
2e A Ph 
H
N O
  
14 ± 0.3 
2f B Cl  
N
 
26.2 ± 4.2 
2g A Ph  OH
OMe
OMe  
17.9 ± 0.3 
2h A Ph  OH 245 
2i A Ph  
N
 
206 ± 30 
2j A Ph n-Pr  >500 
2k A Ph n-Pr OH
OMe
OMe  
82 ± 8 
2l A Ph n-Pr OH >500 
2m A Ph n-Pr 
N
 
100 ± 14 
2n B Cl   99 ± 18 
2o A Cl  OH
OMe
OMe  
42 ± 8 
2p A Cl n-Pr  187 ± 38 
2q A Cl n-Pr OH
OMe
OMe  
5.3 ± 0.9 
2r A Cl n-Pr OH 16.4 ± 1.6 
2s B Cl n-Pr 
N
 
57 ± 6 
2t B Cl 
H
N O
  
91.4 ± 0.4 
2u A Cl 
H
N O
 
OH
OMe
OMe  
76 ± 4 
2v A OSEM  OH
OMe
OMe  
257 ± 34 
2w C OSEM n-Pr  464 ± 31 
2x C OSEM n-Pr OH
OMe
OMe  
118 ± 24 
2y C OSEM n-Pr OH 476 ± 24 
2z C OSEM n-Pr 
N
 
312 ± 22 
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